Post-Market Research Fraud
Recently, Medtronic paid the government over $23.5 million to quiet allegations that it violated the False Claims Act by using physician payments related to post-market…
Read More »Pharma 101 – Pharmaceutical Fraud
Pharmaceutical Fraud News & Insight form the Qui Tam and False Claims Act Perspective
Contact FormCategory Archives: Pharmaceutical
Justice Department Pursues Healthcare Qui Tam Allegations Involving Companies Who Knowingly Manufacture Defective Products
The Justice Department closed out 2015 by intervening and settling a healthcare fraud qui tam action alleging that a pharmaceutical manufacturer knowingly sold defective drug products…
Read More »Fraudulent Labeling: Pharma Company Settles Fraud Charges for Half-Strength Supplements
The Government recently announced a $39 million settlement against Vintage Pharmaceuticals, LLC, d/b/a QUALITEST PHARMACEUTICALS; Vintage’s corporate parent Endo Pharmaceuticals, Inc.; and seven of their…
Read More »Echo: Orphan Drug Manufacturers Marketing Off-Label
Nolan Auerbach & White addressed orphan off label drug marketing in our blog on November 10, 2015. Orphan Drugs are used in the diagnosis, prevention and/or treatment…
Read More »Are Senior Pharma Executives Racing to File Qui Tam Actions?
Over the years, several high-ranking DOJ officials have stated that they will hold pharmaceutical fraud masterminds accountable for their actions. Their words have remained unfulfilled…
Read More »Is the $160 Billion Pfizer Merger with Allergan Unpatriotic?
President Obama has called today's announcement unpatriotic due to the fact that the inversion process, merging a smaller foreign company with a larger one, will…
Read More »Are Orphan Drug Manufacturers Ramping Up Off-Label Marketing Efforts?
Fraud goes where money flows. This statement is particularly true in the growing prescription drug market, which has been fraught with illegal marketing schemes for…
Read More »Novartis to Pay Government $390 Million for Allegedly Paying Kickbacks to Pharmacies
According to recent SEC filings, Novartis AG has agreed to pay the federal government $390 million to settle an intervened False Claims Act (FCA) qui tam…
Read More »Whistleblowers are Needed to Supplement FDA’s Limited “Scientific Base”
In 2007, a subcommittee of the FDA’s Science Board released a report which, among other things, found that the FDA had a “weak scientific base…
Read More »False Claims Act Will Always Reach Off-Label Pharmaceutical Promotions When Promotions Include False or Misleading Information
Nearly three years ago, the Second Circuit Court of Appeals vacated the criminal conviction of a pharmaceutical sales representative, who was convicted of conspiring to…
Read More »